1
|
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood 2022; 140:2805-2817. [PMID: 36283106 DOI: 10.1182/blood.2022017326] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 10/05/2022] [Accepted: 10/21/2022] [Indexed: 01/17/2023] Open
Abstract
Myelofibrosis (MF) is a disease associated with high unmet medical needs because allogeneic stem cell transplantation is not an option for most patients, and JAK inhibitors are generally effective for only 2 to 3 years and do not delay disease progression. MF is characterized by dysplastic megakaryocytic hyperplasia and progression to fulminant disease, which is associated with progressively increasing marrow fibrosis. Despite evidence that the inflammatory milieu in MF contributes to disease progression, the specific factors that promote megakaryocyte growth are poorly understood. Here, we analyzed changes in the cytokine profiles of MF mouse models before and after the development of fibrosis, coupled with the analysis of bone marrow populations using single-cell RNA sequencing. We found high interleukin 13 (IL-13) levels in the bone marrow of MF mice. IL-13 promoted the growth of mutant megakaryocytes and induced surface expression of transforming growth factor β and collagen biosynthesis. Similarly, analysis of samples from patients with MF revealed elevated levels of IL-13 in the plasma and increased IL-13 receptor expression in marrow megakaryocytes. In vivo, IL-13 overexpression promoted disease progression, whereas reducing IL-13/IL-4 signaling reduced several features of the disease, including fibrosis. Finally, we observed an increase in the number of marrow T cells and mast cells, which are known sources of IL-13. Together, our data demonstrate that IL-13 is involved in disease progression in MF and that inhibition of the IL-13/IL-4 signaling pathway might serve as a novel therapeutic target to treat MF.
Collapse
|
2
|
Wang X, Lai Q, Zheng B, Ye L, Wen S, Yan Y, Yang B, Man MQ. Both Prevalence and Severity of Pruritus are Associated with Age in Chinese Patients with Skin Diseases. Clin Cosmet Investig Dermatol 2021; 14:217-223. [PMID: 33692631 PMCID: PMC7939505 DOI: 10.2147/ccid.s300458] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Accepted: 02/12/2021] [Indexed: 11/23/2022]
Abstract
BACKGROUND Although the characteristics of pruritus in some skin diseases are documented, characteristics of pruritus related to gender-, age-, and skin disorder have not yet been well defined. OBJECTIVE To characterize dermatosis-associated pruritus in Chinese patients. METHODS A cross-sectional study was carried out in a single center. The intensity of pruritus was evaluated using a 0-10 visual analog scale (VAS). Skin disorders were diagnosed by dermatologists. The prevalence and intensity of pruritus were compared among skin disorders, and between males and females. RESULTS Valid questionnaires were obtained from 1,246 female and 864 male patients. Patients with acne, eczematous dermatitis, and urticaria accounted for 18%, 17%, and 14%, respectively. Both the prevalence and severity of pruritus varied greatly with skin disorders (p<0.0001). Patients with either urticaria or eczematous dermatitis displayed a higher prevalence of pruritus (92% and 82%, respectively), while subjects with urticaria exhibited the highest VAS in comparison to those with other skin disorders (p<0.05 to p<0.001 vs the others). Moreover, both the prevalence and severity of pruritus were positively associated with age in both males and females (p<0.0001). Furthermore, 60 out of 77 patients (78%) with topical glucocorticoid-induced dermatitis experienced pruritus, with a VAS of 2.03±0.21. Finally, a lower VAS was found in subjects with oily skin than those with either dry or normal skin. CONCLUSION The prevalence and severity of pruritus vary with skin disorders, skin type, age, and gender in Chinese patients.
Collapse
Affiliation(s)
- Xiaohua Wang
- Dermatology Hospital, Southern Medical University, Guangdong, 510091, People’s Republic of China
| | - Qingsong Lai
- Center for Chronic Disease Prevention and Control of Puning City, Puning, Guangdong, 515300, People’s Republic of China
| | - Baoqing Zheng
- Dermatology Hospital, Southern Medical University, Guangdong, 510091, People’s Republic of China
| | - Li Ye
- Dermatology Hospital, Southern Medical University, Guangdong, 510091, People’s Republic of China
| | - Si Wen
- Dermatology Hospital, Southern Medical University, Guangdong, 510091, People’s Republic of China
| | - Yunling Yan
- Dermatology Hospital, Southern Medical University, Guangdong, 510091, People’s Republic of China
| | - Bin Yang
- Dermatology Hospital, Southern Medical University, Guangdong, 510091, People’s Republic of China
| | - Mao-Qiang Man
- Dermatology Hospital, Southern Medical University, Guangdong, 510091, People’s Republic of China
| |
Collapse
|
3
|
Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG. Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms. Curr Hematol Malig Rep 2020; 14:145-153. [PMID: 31119475 DOI: 10.1007/s11899-019-00508-w] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
PURPOSE OF REVIEW Chronic inflammation is a characteristic feature of myeloproliferative neoplasm (MPN) and impacts many aspects of the disease including initiation, progression, and symptomatology. RECENT FINDINGS The chronic inflammatory state of MPN results from disruption of immune signaling pathways leading to overproduction of inflammatory cytokines by both the neoplastic clones and bystander immune cells. This chronic inflammation may allow for the neoplastic clone to gain a selective advantage. The symptomatic burden felt by MPN patients may be a result of the chronic inflammation associated with MPN, as several cytokines have been linked with different symptoms. Pharmacologic as well as nonpharmacologic treatments of the inflammatory component of this disease may lead to decreased symptomatic burden, prevention of disease progression, and improvement in overall disease trajectory. Inflammation plays a key role in the pathogenesis of MPN and represents an important therapeutic target.
Collapse
Affiliation(s)
- Laura F Mendez Luque
- Department of Biological Chemistry, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA
| | - Amanda L Blackmon
- Division of Hematology/Oncology, Department of Medicine, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA
| | - Gajalakshmi Ramanathan
- Division of Hematology/Oncology, Department of Medicine, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA
| | - Angela G Fleischman
- Department of Biological Chemistry, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA. .,Division of Hematology/Oncology, Department of Medicine, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA. .,Chao Family Comprehensive Cancer Center, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA.
| |
Collapse
|
4
|
Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RS. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight 2020; 5:121781. [PMID: 31941838 PMCID: PMC7030823 DOI: 10.1172/jci.insight.121781] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 12/04/2019] [Indexed: 12/13/2022] Open
Abstract
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by cytopenia and extramedullary hematopoiesis, resulting in splenomegaly. Multiple pathological mechanisms (e.g., circulating cytokines and genetic alterations, such as JAKV617F mutation) have been implicated in the etiology of MF, but the molecular mechanism causing resistance to JAK2V617F inhibitor therapy remains unknown. Among MF patients who were treated with the JAK inhibitor ruxolitinib, we compared noncoding RNA profiles of ruxolitinib therapy responders versus nonresponders and found miR-543 was significantly upregulated in nonresponders. We validated these findings by reverse transcription-quantitative PCR. in this same cohort, in 2 additional independent MF patient cohorts from the United States and Romania, and in a JAK2V617F mouse model of MF. Both in vitro and in vivo models were used to determine the underlying molecular mechanism of miR-543 in MF. Here, we demonstrate that miR-543 targets the dioxygenases ten-eleven translocation 1 (TET1) and 2 (TET2) in patients and in vitro, causing increased levels of global 5-methylcytosine, while decreasing the acetylation of histone 3, STAT3, and tumor protein p53. Mechanistically, we found that activation of STAT3 by JAKs epigenetically controls miR-543 expression via binding the promoter region of miR-543. Furthermore, miR-543 upregulation promotes the expression of genes related to drug metabolism, including CYP3A4, which is involved in ruxolitinib metabolism. Our findings suggest miR-543 as a potentially novel biomarker for the prognosis of MF patients with a high risk of treatment resistance and as a potentially new target for the development of new treatment options.
Collapse
Affiliation(s)
| | | | - Taghi Manshouri
- Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | - Andreia M. Silva
- Department of Experimental Therapeutics and
- Instituto de Investigação e Inovação em Saúde (i3S)
- Instituto de Engenharia Biomédica (INEB), and
- Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - Cristina Ivan
- Department of Experimental Therapeutics and
- Center for RNA Interference and Non-coding RNAs, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | - Diana Gulei
- Department of Experimental Therapeutics and
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
- Department of Functional Genomics, The Oncology Institute, Cluj-Napoca, Romania
| | | | - Nayra Soares do Amaral
- Department of Experimental Therapeutics and
- Molecular Morphology Laboratory, Department of Investigative Pathology, AC Camargo Cancer Center, São Paulo, Brazil
| | - Pilar Mur
- Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Cristina Perez
- Department of Experimental Therapeutics and
- Mayagüez Campus, University of Puerto Rico, Mayagüez, Puerto Rico, USA
| | - Elizabeth Torres-Claudio
- Department of Experimental Therapeutics and
- University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA
| | - Mihnea P. Dragomir
- Department of Experimental Therapeutics and
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
- Department of Surgery, Fundeni Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | | | | | | | - Leonard Golfman
- Department of Pediatrics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | | | - Xinna Zhang
- Center for RNA Interference and Non-coding RNAs, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | - Wanke Zhao
- Department of Pathology, Health Sciences Center, University of Oklahoma, Oklahoma City, Oklahoma, USA
| | - Wanting Tina Ho
- Department of Pathology, Health Sciences Center, University of Oklahoma, Oklahoma City, Oklahoma, USA
| | - Marcos Roberto Estecio
- Department of Epigenetics and Molecular Carcinogenesis and
- Center for Cancer Epigenetics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | | | - Ciprian Tomuleasa
- Department of Hematology, The Oncology Institute Ion Chiricuta, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
| | - Ioana Berindan-Neagoe
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
- Department of Functional Genomics, The Oncology Institute, Cluj-Napoca, Romania
| | | | - Zeev Estrov
- Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | - Zhizhuang J. Zhao
- Department of Pathology, Health Sciences Center, University of Oklahoma, Oklahoma City, Oklahoma, USA
| | - Srdan Verstovsek
- Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | - George A. Calin
- Department of Experimental Therapeutics and
- Center for RNA Interference and Non-coding RNAs, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
| | | |
Collapse
|
5
|
Mast cell activation in the context of elevated basal serum tryptase: genetics and presentations. Curr Allergy Asthma Rep 2019; 19:55. [PMID: 31776770 DOI: 10.1007/s11882-019-0887-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
PURPOSE OF REVIEW To describe inherited and acquired genetic variants and clinical entities associated with increased basal serum tryptase (BST), distinguish these levels from those which acutely rise due to mast cell activation, and finally to characterize the association between chronically elevated basal serum tryptase and episodic mast cell activation. RECENT FINDINGS Hereditary alpha-tryptasemia is a commonly inherited genetic cause for basally elevated serum tryptase and explains elevated BST in many individuals who do not have evidence of clonal myeloid or mast cell disease. When clonal myeloid disease is present, BST may be elevated and can be a biomarker of a number of disparate disorders of the myeloid compartment. Elevated BST is most commonly caused by hereditary alpha tryptasemia but may also be indicative of clonal myeloid disease. Clinical reports suggest that elevated BST is associated with increased risk for more severe systemic allergic reactions to a number of eliciting agents and exposures. Additional studies are needed to determine the role that inherited or acquired genetic variants associated with elevated BST and clonal or non-clonal myeloid diseases may play in these reactions.
Collapse
|
6
|
Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol 2019; 144:375-380. [DOI: 10.1016/j.jaci.2019.04.005] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 04/03/2019] [Accepted: 04/09/2019] [Indexed: 12/12/2022]
|
7
|
Pilkington S, Barron M, Watson R, Griffiths C, Bulfone‐Paus S. Aged human skin accumulates mast cells with altered functionality that localize to macrophages and vasoactive intestinal peptide-positive nerve fibres. Br J Dermatol 2019; 180:849-858. [PMID: 30291626 PMCID: PMC6619242 DOI: 10.1111/bjd.17268] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2018] [Indexed: 12/21/2022]
Abstract
BACKGROUND Skin health declines with age and this is partially attributed to immunosenescence. Mast cells (MCs) are innate immune cells that coordinate tissue immune responses integral to skin homeostasis and disease. OBJECTIVES To understand how MCs contribute to human skin ageing, we investigated how intrinsic ageing impacts MC phenotype and MC relationships with other immune cells and skin structures. METHODS In photoprotected skin biopsies from young (≤ 30 years) and aged (≥ 75 years) individuals, immunostaining and spatial morphometry were performed to identify changes in MC phenotype, number, distribution and interaction with the vasculature and nerve fibres. Quantitative polymerase chain reaction was used to measure changes in gene expression related to immune cell activity and neuropeptide signalling. RESULTS Skin MCs, macrophages and CD8+ T cells increased in number in intrinsically aged vs. young skin by 40%, 44% and 90%, respectively (P < 0·05), while CD4+ T cells and neutrophils were unchanged. In aged skin, MCs were more numerous in the papillary dermis and showed a reduced incidence of degranulation (50% lower than in young, P < 0·01), a conserved tryptase-chymase phenotype and coexpression of granzyme B. In aged skin, MCs increased their association with macrophages (~ 48% vs. ~27%, P < 0·05) and nerve fibres (~29% vs. 16%, P < 0·001), while reducing their interactions with blood vessels (~34% vs. 45%, P < 0·001). Additionally, we observed modulation of gene expression of vasoactive intestinal peptide (VIP; increased) and substance P (decreased) with age; this was associated with an increased frequency of VIP+ nerve fibres (around three times higher in aged skin, P < 0·05), which were strongly associated with MCs (~19% in aged vs. 8% in young, P < 0·05). CONCLUSIONS In photoprotected skin we observed an accumulation of MCs with increasing age. These MCs have both altered functionality and distribution within the skin, which supports a role for these cells in altered tissue homeostasis during ageing.
Collapse
Affiliation(s)
- S.M. Pilkington
- Centre for Dermatology Research, School of Biological Sciences, Faculty of Biology, Medicine and HealthManchester Academic Health Science CentreThe University of ManchesterManchesterM13 9PTU.K
- The Dermatology CentreSalford Royal NHS Foundation TrustSalfordM6 8HDU.K
| | - M.J. Barron
- Centre for Dermatology Research, School of Biological Sciences, Faculty of Biology, Medicine and HealthManchester Academic Health Science CentreThe University of ManchesterManchesterM13 9PTU.K
- The Dermatology CentreSalford Royal NHS Foundation TrustSalfordM6 8HDU.K
| | - R.E.B. Watson
- Centre for Dermatology Research, School of Biological Sciences, Faculty of Biology, Medicine and HealthManchester Academic Health Science CentreThe University of ManchesterManchesterM13 9PTU.K
- The Dermatology CentreSalford Royal NHS Foundation TrustSalfordM6 8HDU.K
| | - C.E.M. Griffiths
- Centre for Dermatology Research, School of Biological Sciences, Faculty of Biology, Medicine and HealthManchester Academic Health Science CentreThe University of ManchesterManchesterM13 9PTU.K
- The Dermatology CentreSalford Royal NHS Foundation TrustSalfordM6 8HDU.K
| | - S. Bulfone‐Paus
- Centre for Dermatology Research, School of Biological Sciences, Faculty of Biology, Medicine and HealthManchester Academic Health Science CentreThe University of ManchesterManchesterM13 9PTU.K
- The Dermatology CentreSalford Royal NHS Foundation TrustSalfordM6 8HDU.K
| |
Collapse
|
8
|
Emrick JJ, Mathur A, Wei J, Gracheva EO, Gronert K, Rosenblum MD, Julius D. Tissue-specific contributions of Tmem79 to atopic dermatitis and mast cell-mediated histaminergic itch. Proc Natl Acad Sci U S A 2018; 115:E12091-E12100. [PMID: 30463955 PMCID: PMC6305010 DOI: 10.1073/pnas.1814132115] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Atopic dermatitis (AD) is the most common skin disease in children. It is characterized by relapsing inflammation, skin-barrier defects, and intractable itch. However, the pathophysiology of itch in AD remains enigmatic. Here, we examine the contribution of Tmem79, an orphan transmembrane protein linked to AD in both mice and humans. We show that Tmem79 is expressed by both keratinocytes and sensory neurons, but that loss of keratinocytic Tmem79 is sufficient to elicit robust scratching. Tmem79-/- mice demonstrate an accumulation of dermal mast cells, which are diminished following chronic treatment with cyclooxygenase inhibitors and an EP3 receptor antagonist. In Tmem79-/- mice, mast cell degranulation produces histaminergic itch in a histamine receptor 1/histamine receptor 4 (H4R/H1R)-dependent manner that may involve activation of TRPV1- afferents. TMEM79 has limited sequence homology to a family of microsomal glutathione transferases and confers protection from cellular accumulation of damaging reactive species, and may thus play a role in regulating oxidative stress. In any case, mechanistic insights from this model suggest that therapeutics targeting PGE2 and/or H1R/H4R histaminergic signaling pathways may represent useful avenues to treat Tmem79-associated AD itch. Our findings suggest that individuals with mutations in Tmem79 develop AD due to the loss of protection from oxidative stress.
Collapse
Affiliation(s)
- Joshua J Emrick
- Department of Physiology, University of California, San Francisco, CA 94143
- School of Dentistry, University of California, San Francisco, CA 94143
| | - Anubhav Mathur
- Department of Dermatology, University of California, San Francisco, CA 94143
| | - Jessica Wei
- Vision Science Graduate Program, School of Optometry, University of California, Berkeley, CA 94720
| | - Elena O Gracheva
- Department of Physiology, University of California, San Francisco, CA 94143
| | - Karsten Gronert
- Vision Science Graduate Program, School of Optometry, University of California, Berkeley, CA 94720
| | - Michael D Rosenblum
- Department of Dermatology, University of California, San Francisco, CA 94143
| | - David Julius
- Department of Physiology, University of California, San Francisco, CA 94143;
| |
Collapse
|
9
|
Stigmasterol Alleviates Cutaneous Allergic Responses in Rodents. BIOMED RESEARCH INTERNATIONAL 2018; 2018:3984068. [PMID: 30140696 PMCID: PMC6081592 DOI: 10.1155/2018/3984068] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 05/14/2018] [Accepted: 06/25/2018] [Indexed: 12/16/2022]
Abstract
The therapeutic potential of stigmasterol, a natural steroid alcohol with established immune-modulatory properties, was assessed on allergic cutaneous responses. We examined its suppressive effect on immunoglobulin E (IgE)-mediated active cutaneous anaphylaxis (ACA), compound 48/80 (C48/80)-induced pruritus, and irritant dermatitis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). Stigmasterol at 10–100 mg/kg significantly inhibited ACA with reduction in reaction area and concentration of the extravasated Evans blue dye. Given at 50 and 100 mg/kg, stigmasterol significantly inhibited C48/80-induced scratching behaviour when compared to saline-treated C48/80-injected control. Skin histopathology of injected sites confirmed that stigmasterol reduced mast cell trafficking and degranulation associated with C48/80-induced pruritus. Stigmasterol controlled inflammatory features such as ear skin oedema and neutrophilia and also reduced serum levels of TNFα induced by topical application of TPA. Epidermal layer thickening and inflammatory cell infiltration of ear skin tissue were significantly reduced by stigmasterol. Taken together, stigmasterol demonstrates significant potential as a molecule of interest in allergic skin disease therapy.
Collapse
|
10
|
Ständer S. „Water Stress“: selten, unverstanden und unlösbar - und doch relevant. J Dtsch Dermatol Ges 2017; 15:595-596. [DOI: 10.1111/ddg.13239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, Berthou C, Ugo V, Carré JL, Misery L, Ianotto JC. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol 2016; 176:255-258. [PMID: 27291777 DOI: 10.1111/bjd.14809] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- C Le Gall-Ianotto
- Laboratory of Neurosciences of Brest, University of Brest, Brest, France.,Department of Dermatology, University Hospital of Brest, Brest, France
| | - E Brenaut
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - M Gouillou
- CIC INSERM 0502, University Hospital of Brest, Brest, France
| | - K Lacut
- CIC INSERM 0502, University Hospital of Brest, Brest, France
| | - E Nowak
- CIC INSERM 0502, University Hospital of Brest, Brest, France
| | - A Tempescul
- Department of Haematology, University Hospital of Brest, Brest, France
| | - C Berthou
- Department of Haematology, University Hospital of Brest, Brest, France
| | - V Ugo
- Laboratory of Haematology, University Hospital of Angers, Angers, France
| | - J L Carré
- Laboratory of Neurosciences of Brest, University of Brest, Brest, France.,Laboratory of Biochemistry, University Hospital of Brest, Brest, France
| | - L Misery
- Laboratory of Neurosciences of Brest, University of Brest, Brest, France.,Department of Dermatology, University Hospital of Brest, Brest, France
| | - J C Ianotto
- CIC INSERM 0502, University Hospital of Brest, Brest, France.,Department of Haematology, University Hospital of Brest, Brest, France
| |
Collapse
|
12
|
Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediators Inflamm 2015; 2015:284706. [PMID: 26538823 PMCID: PMC4619953 DOI: 10.1155/2015/284706] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Accepted: 08/09/2015] [Indexed: 12/11/2022] Open
Abstract
Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic instability, dysregulated signaling pathways, and subsequent overproduction of inflammatory markers. Acknowledged for their debilitating symptom profiles, recent investigations have aimed to determine the identity of these markers, the upstream sources stimulating their development, their prevalence within the MPN population, and the role they play in symptom development. Creation of dedicated Patient Reported Outcome (PRO) tools, in combination with expanded access to cytokine analysis technology, has resulted in a surge of investigations evaluating the potential associations between symptoms and inflammation. Emerging data demonstrates clear relationships between individual MPN symptoms (fatigue, abdominal complaints, microvascular symptoms, and constitutional symptoms) and cytokines, particularly IL-1, IL-6, IL-8, and TNF-α. Information is also compiling on the role symptoms paradoxically play in the development of cytokines, as in the case of fatigue-driven sedentary lifestyles. In this paper, we explore the symptoms inherent to the MPN disorders and the potential role inflammation plays in their development.
Collapse
|
13
|
Kawakami T, Ando T, Kawakami Y. Hypothetical Atopic Dermatitis-Myeloproliferative Neoplasm Syndrome. Front Immunol 2015; 6:434. [PMID: 26379670 PMCID: PMC4547498 DOI: 10.3389/fimmu.2015.00434] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Accepted: 08/10/2015] [Indexed: 12/29/2022] Open
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease. Myeloproliferative neoplasms (MPNs) are hematopoietic malignancies caused by uncontrolled proliferation of hematopoietic stem/progenitor cells. Recent studies have described several mutant mice exhibiting both AD-like skin inflammation and MPN. Common pathways for skin inflammation encompass overexpression of thymic stromal lymphopoietin and reduced signaling of epidermal growth factor receptor in the epidermis, while overproduction of granulocyte-colony-stimulating factor by keratinocytes and constitutive activation of Stat5 in hematopoietic stem cells are important for the development of MPN. The murine studies suggest the existence of a similar human disease tentatively termed as the atopic dermatitis-myeloproliferative neoplasm syndrome.
Collapse
Affiliation(s)
- Toshiaki Kawakami
- Division of Cell Biology, La Jolla Institute for Allergy and Immunology , La Jolla, CA , USA ; Laboratory for Allergic Disease, RIKEN Center for Integrative Medical Sciences (IMS-RCAI) , Yokohama , Japan
| | - Tomoaki Ando
- Laboratory for Allergic Disease, RIKEN Center for Integrative Medical Sciences (IMS-RCAI) , Yokohama , Japan
| | - Yuko Kawakami
- Division of Cell Biology, La Jolla Institute for Allergy and Immunology , La Jolla, CA , USA
| |
Collapse
|
14
|
Zhao W, Ho WTT, Zhao ZJ. Quantitative analyses of myelofibrosis by determining hydroxyproline. Stem Cell Investig 2015; 2:2. [PMID: 27358870 DOI: 10.3978/j.issn.2306-9759.2015.01.02] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 01/12/2015] [Indexed: 11/14/2022]
Abstract
BACKGROUND Myeloproliferative neoplasms (MPNs) are blood malignancies manifested in increased production of red blood cells, white blood cells, and/or platelets. Myelofibrosis is a subtype of MPNs characterized by the formation of scar-like tissues in the bone marrow due to abnormal hematopoiesis. It is considered a disease of both hematopoietic stem cells and stem cell niches. Patients with myelofibrosis have very poor prognosis, and there is no effective treatment so far. Myelofibrosis has routinely been detected by using histochemical staining methods which produce qualitative rather than quantitative results. In this study, we developed a quantitative assay of bone marrow myelofibrosis in JAK2V617F transgenic mice by determining hydroxyproline. METHODS The JAK2V617F transgenic mice's tissue was collected to detect the bone marrow myelofibrosis. Statistical analyses were performed using the GraphPad Prism program. Differences of samples between two groups were accessed using t tests. P values less than 0.05 (2-tailed) were considered significantly different. RESULTS We developed a quantitative method for detecting myelofibrosis by analyzing the content of hydroxyproline, a modified amino acid largely restricted to collagen which forms the fibrotic structure in bone marrow tissues. Our study also demonstrated age-dependent development of bone marrow myelofibrosis in JAK2V617F transgenic mice. CONCLUSIONS In the present study, we have developed a new method for detecting bone marrow myelofibrosis by analyzing hydroxyproline contents. The method is highly sensitive and accurate. It provides more accurate, representative, and quantitative information than histochemical analyses. We believe that this method should find wide applications for analyzing the progression of myelofibrosis and efficacy of drug treatment.
Collapse
Affiliation(s)
- Wanke Zhao
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
| | - Wan-Ting Tina Ho
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
| | - Zhizhuang Joe Zhao
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
| |
Collapse
|